Gene expression data from 4T1 irradiated tumors treated with TGFbeta blockade
Data and Resources
-
Gene expression data from 4T1 irradiated...HTML
GeneLab Study Page
| Field | Value |
|---|---|
| accessLevel | public |
| accrualPeriodicity | irregular |
| bureauCode | {026:00} |
| catalog_@context | https://project-open-data.cio.gov/v1.1/schema/catalog.jsonld |
| catalog_@id | https://data.nasa.gov/data.json |
| catalog_conformsTo | https://project-open-data.cio.gov/v1.1/schema |
| catalog_describedBy | https://project-open-data.cio.gov/v1.1/schema/catalog.json |
| identifier | nasa_genelab_GLDS-160 |
| issued | 2018-06-26 |
| landingPage | https://data.nasa.gov/d/t729-nms2 |
| modified | 2020-01-29 |
| programCode | {026:005} |
| publisher | National Aeronautics and Space Administration |
| resource-type | Dataset |
| source_datajson_identifier | true |
| source_hash | 0e162d4089c96466cc563005f5a012238ac7d85e |
| source_schema_version | 1.1 |
| theme | {"Earth Science"} |
| Groups |
|
| Tags |
|
| isopen | False |
| license_id | notspecified |
| license_title | License not specified |
| maintainer | GeneLab Outreach |
| maintainer_email | genelab-outreach@lists.nasa.gov |
| metadata_created | 2025-11-22T07:46:39.076562 |
| metadata_modified | 2025-11-22T07:46:39.076566 |
| notes | Accumulating data support the concept that ionizing radiation therapy (RT) has the potential to convert the tumor into an in situ individualized vaccine; however this potential is rarely realized by RT alone. Transforming growth factor xce xb2 (TGF xce xb2) is an immunosuppressive cytokine that is activated by RT and inhibits the antigen-presenting function of dendritic cells and the differentiation of effector CD8+ T cells. Here we tested the hypothesis that TGF xce xb2 hinders the ability of RT to promote anti-tumor immunity. Development of tumor-specific immunity was examined in a pre-clinical model of metastatic breast cancer. Mice bearing established 4T1 mouse mammary carcinoma treated with pan-isoform specific TGF xce xb2 neutralizing antibody 1D11 showed significantly improved control of the irradiated tumor and non-irradiated metastases but no effect in the absence of RT. Notably whole tumor transcriptional analysis demonstrated the selective upregulation of genes associated with immune-mediated rejection only in tumors of mice treated with RT+TGF xce xb2 blockade. Mice treated with RT+TGF xce xb2 blockade exhibited cross-priming of CD8+ T cells producing IFN xce xb3 in response to three tumor-specific antigens in tumor-draining lymph nodes which was not evident for single modality treatment. Analysis of the immune infiltrate in mouse tumors showed a significant increase in CD4+ and CD8+ T cells only in mice treated with the combination of RT+TGF xce xb2 blockade. Depletion of CD4+ or CD8+ T cells abrogated the therapeutic benefit of RT+TGF xce xb2 blockade. These data identify TGF xce xb2 as a master inhibitor of the ability of RT to generate an in situ tumor vaccine which supports testing inhibition of TGF xce xb2 during radiotherapy to promote therapeutically effective anti-tumor immunity. We used genome-wide microarray to depict main biological processes responsibles for the therapeutic benefit of the combination ofTGF-beta blockade and local radiotherapy. To gain a more comprehensice protrait of the effects of RT and TGFbeta blockade on gene expressionin tumors we collected 4T1 tumors 4 days after completion of RT. Three tumors from each group were then subjected to RNA extraction and hybridization on affymetrix array. |
| num_resources | 1 |
| num_tags | 25 |
| title | Gene expression data from 4T1 irradiated tumors treated with TGFbeta blockade |